Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Novartis to Buy All of Speedel

July 14, 2008 | A version of this story appeared in Volume 86, Issue 28

Novartis will pay a total of $880 million to first increase its stake in the Swiss biopharmaceutical firm Speedel from 9.7% to 61.4% and then buy the rest through a public offering. Novartis upped its stake by buying shares from five shareholders, including Speedel founder and CEO Alice Huxley, who held 21.5%. In 1998, Novartis helped fund Speedel's creation and gave it rights to the cardiovascular drug aliskiren, only to buy back rights in 2002. Approved in the U.S. and Europe in 2007, the drug, called Tekturna in the U.S., is the first in a new class of direct rennin inhibitors. The acquisition means that Novartis will no longer have to pay royalties and manufacturing fees to Speedel.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.